Maravai LifeSciences Holdings, Inc. MRVI
7.72 USD +0.27 (+3.62%)
At closeNov 4, 2026, 5:31 PM EST
7.80 +0.08 +1.04%
After hours · Nov 4, 5:31 PM ET
7.28 Day range 7.89
2.55 52-week range 9.42
- YTD
- +137.54%
- 1 year
- +168.99%
Analyst view
Consensus: buy
Buy
Price target (mean) 8.50 +10.1% upside
Now 7.72
- Target (low)
- 7.00
- Target (mean)
- 8.50
- Target (high)
- 12.00
Ratings (0m) 9 5 buy · 4 hold · 0 sell
- Strong buy0
- Buy5
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05584 | -0.07725 – -0.04 | -0.08 | +30.2% | 43.56M | +4.6% | 9 |
| Next quarter | -0.04406 | -0.06603 – -0.03 | -0.04 | -10.2% | 50.92M | +2.1% | 8 |
| Current year | -0.10739 | -0.15032 – -0.08 | -0.29 | +63.0% | 211.77M | +14.0% | 9 |
| Next year | -0.10066 | -0.20 – -0.02 | -0.10739 | +6.3% | 224.89M | +6.2% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 7, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Dec 15, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 12, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 12, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| May 13, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| May 13, 2025 | Baird | Maintained | Neutral | Neutral |
| Mar 25, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 21, 2025 | UBS | Maintained | Neutral | Neutral |
| Mar 3, 2025 | B of A Securities | Maintained | Buy | Buy |
| Feb 26, 2025 | Baird | Downgrade | Outperform | Neutral |
| Dec 5, 2024 | Goldman Sachs | Downgrade | Neutral | Sell |
| Nov 14, 2024 | Wolfe Research | Initiated | — | Peer Perform |
| Nov 8, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 8, 2024 | William Blair | Downgrade | Outperform | Market Perform |
| Nov 8, 2024 | Baird | Maintained | Outperform | Outperform |
| Oct 8, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 27, 2024 | Wells Fargo | Initiated | — | Overweight |
| Aug 16, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 13, 2024 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Aug 8, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 8, 2024 | UBS | Maintained | Neutral | Neutral |
| Jul 9, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 9, 2024 | Baird | Maintained | Outperform | Outperform |
| Apr 10, 2024 | Craig-Hallum | Initiated | — | Buy |
| Feb 23, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 23, 2024 | Stifel | Maintained | Buy | Buy |
| Dec 12, 2023 | B of A Securities | Upgrade | Neutral | Buy |
| Nov 9, 2023 | Goldman Sachs | Maintained | Neutral | Neutral |